Chemistry, Probes & Molecular Therapy (CPMT)

The Chemistry, Probes and Molecular Therapy (CPMT) research group in the Department of Radiology and Biomedical Imaging at UCSF focuses on the development of new molecular imaging tools. This research group will complement our existing research and infrastructure groups to bring targeted therapies to the clinic, for both for the diagnosis and therapy of human disease.

About Chemistry, Probes & Molecular Therapy (CPMT)

CPMT conference schedule

Meetings related to the activities of the Chemistry, Probes and Molecular Therapy (CPMT) group will be held on Tuesday afternoons, at China Basin Landing in room 342, unless otherwise noted. The goal is 4-5PM with the exception of longer faculty meetings. These include:

  1. CPMT faculty meetings. These are held quarterly and include AIT SRG faculty members.
  2. Clinical research in progress (CRIP). These are designed for clinical researchers to discuss projects.
  3. Nuclear imaging research. Postdoctoral fellows in the Wilson, VanBrocklin, Flavell, and Evans labs will be presenting biweekly. Researchers at all levels from Mission Bay groups are invited to join.
  4. Visiting speakers. Invited speakers will present on Tuesday afternoons. We welcome suggestions from all CPMT members.

Barbara Green ([email protected]) will be our contact administrator for the CPMT and related research meetings.

Nov 17
Sinan Wang, PhD (Flavell group)
Title: CD46-targeted PET imaging on PDX model of prostate cancer and preliminary study of CD46-targeted radionuclide therapy
Abstract: CD46 has recently been identified as a novel and underexplored therapeutic target in prostate cancer (PCa). We evaluated the of CD46-targeted PET probe [89Zr]DFO-YS5 in three patient derived xenograft models and compared it with PSMA-based PET probe 68GA-PSMA11.  A few preliminary CD46-targeted therapy studies were also performed using 177Lu or 225Ac-labeled YS5.
Nov 24 Canceled
Dec 1 Canceled
Dec 8 Alexandre Sorlin (Wilson group)
Title: Iridium Catalyzed Allylic Fluorination: Scope, Mechanism and Applications
Dec 15 Canceled
Dec 22 Henry Charles Manning (Guest speaker- Host: Wilson)
Title: Opportunities and Directrions in Cancer Metabolism Research Enabled by Quantitative Imaging
Dec 29 Canceled
Jan 5 Jianghong Rao, Stanford (Guest speaker- Host: Wilson)
Title: A general strategy for multimodality imaging of proteolytic enzyme activity
Abstract: Dr. Rao received his PhD in Chemistry from Harvard University in 1999 and completed a Damon Runyon Cancer Research Foundation postdoctoral fellowship at UCSD in 2001 before joining Department of Molecular Pharmacology at UCLA as assistant professor. He moved to Stanford University in 2004 where he is Professor of Radiology and Chemistry, a member of the Molecular Imaging Program at Stanford (MIPS) and faculty fellow of Stanford ChEM-H. His research interest includes molecular probe chemistry, nanomaterials and nanotechnology, in vitro diagnostics, multimodality molecular imaging, and cancer theranostics. His work has been described in over 120 peer-reviewed articles in scientific journals and 24 patents/patent applications. He is an elected fellow of the American Institute for Medical and Biological Engineering (AIMBE) and a distinguished investigator of the Academy for Radiology & Biomedical Imaging Research.
Jan 12 SRG meeting
Jan 19 Aisling Chaney, PhD - Stanford University (Guest Speaker - Host: VanBrocklin)
Title: Illuminating the role of inflammation in neurodegenerative disease using novel molecular imaging strategies
Jan 26 Illona Polvoy (WIlson group)
Feb 2 Sang Hee Lee (Guest Speaker - Host: Wilson)
Title: Development of imidazo[1,2-a]pyridine derivatives TSPO ligands for theranostic application in diseases with overexpression of TSPO
Abstract: The translocator protein 18kDa (TSPO) is located on the outer membrane of mitochondrial, widely used as a biomarker of neuroinflammation and cancers. As a biomarker for neuroinflammation, a high expression of TSPO is observed in activated microglia; especially observed in neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and multiple sclerosis. Furthermore, expression of TSPO is also related with some cancers, such as brain, oral, breast, colon, ovarian and prostate cancers. For this reason, the development of TSPO targeted imaging and therapeutic ligands may help monitor the progression of pathologies and help assess the efficacy of therapies. In this study, we developed imidazo[1,2-a]pyridine derivative TSPO ligands for theranostic application in disease with TSPO overexpression.
Feb 9 Thomas Hope - Clinical Research in Progress
Feb 16 Anil Parsram Bidkar (Flavell group)
Title: Nanocarrier Based Drug Delivery Systems for Cancer Cell Targeting
Abstract: To attain maximum therapeutic efficacy of a drug and minimize its undesirable effects on the off-target sites, proper delivery of a drug to the affected site is indispensable. For this purpose, in recent years, nanocarriers are used to deliver the drug molecules specifically to the cancer cells via enhanced permeability and retention (EPR) effect and by active targeting. In several instances, conjugation of a ligand on the nanocarriers' surface has also aided in targeting the drug-loaded nanocarrier specifically to the cancer cells. Here, I will discuss about my Ph.D. project, which primarily revolves around the concept of drug delivery, explicitly to cancer cells. For the work, we have prepared Selenium and RBC membrane-based nanocarriers for anti-cancer drug delivery. Thereafter, the targeting and the therapeutic efficiency of the fabricated drug-loaded nanocarriers were evaluated in monolayer cells and 3D spheroid systems.
Feb 23 Shalini Chopra (Evans group)
Talk Title: Targeting CDCP1 expression using immunotherapy
Abstract: CUB domain containing protein 1 (CDCP1) is highly overexpressed in many deadly cancer types. Our previous work has established CDCP1 as a target for radioligand therapy (RLT) in pancreatic cancer. In the present study, we are exploring the potential of monoclonal human recombinant antibodies developed against CDCP1. We are targeting the CDCP1 expression in different cancer types using anti-CDCP1 antibodies. We also aim to test the CDCP1 directed RLT in various tumor types. 
Mar 2 Kayvan Keshari (Guest speaker- Host: Wilson)
Talk Title:  A Tale of Two Sugars
Mar 9 Niranjan Meher (Flavell group)
Mar 16 Gayatri Gowrishankar (Guest speaker- Host: Wilson)
Mar 23 Zhuo Chen (Evans group)
Mar 30 Changhua Mu (Flavell group)
Apr 6 Hyunjung Kim (Evans group)
Apr 13 Suzanne Lapi (Guest speaker- Host: Wilson)
Apr 20 Jaehoon Shin (WIlson group)
Apr 27 Raag Airan (Guest speaker- Host: Wilson)
May 4 Ning Zhao (Evans group)
May 11  
May 18 Joe Blecha (VanBrocklin group)
May 25  

Past Schedule

2020-2021 (pdf)
2019-2020 (pdf)

Who we serve

The CPMT’s research will translate to healthier futures for:

  • Personalized medicine
  • Individual patient care according to unique metabolic, genetic, and biochemical profiles

Conditions we address

The clinical application of our research includes special focus on:

  • Cancer
  • Infection
  • Neurodegenerative disease

Who we partner with

We look forward to building relationships a wide range of partners:

  • Patients and their families
  • Researchers from our own and other institutions
  • Visionaries who seek to serve the populations we do
  • Donors committed to improving the lives of others

Who we are

The CPMT is made up of:

  • Clinical and research faculty
  • Radiochemists, physicists, spectroscopists, and nuclear medicine physicians
  • Postdoctoral fellows
  • Research staff
  • Medical and graduate students